Rob Fox

Rob Fox currently serves as Chief Commercial Officer at tranScrip since January 2025. Prior to this role, Rob Fox held multiple positions at Clinigen from June 2015 to December 2024, including VP Corporate Development and VP Investor Relations and Corporate Development, where responsibilities included formulating M&A strategies, managing investor relations, and overseeing corporate communications. Rob Fox also previously led global business development efforts at Idis from 2003 until its acquisition by Clinigen, where leadership included defining Managed Access strategies and overseeing international business teams for pharmaceutical and biotech partners. Rob Fox holds a BA Hons in Business Economics from the University of Liverpool, earned between 1995 and 1998.